Solid Biosciences Inc.
SLDB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $8,094 | $13,620 |
| % Growth | – | -100% | -40.6% | – |
| Cost of Goods Sold | $2,455 | $2,581 | $0 | $0 |
| Gross Profit | -$2,455 | -$2,581 | $8,094 | $13,620 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $96,431 | $76,563 | $78,420 | $58,739 |
| G&A Expenses | $33,297 | $27,752 | $28,948 | $27,135 |
| SG&A Expenses | $33,297 | $27,752 | $28,948 | $27,135 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,455 | -$2,581 | $7,178 | $0 |
| Operating Expenses | $127,273 | $101,734 | $114,546 | $85,874 |
| Operating Income | -$129,728 | -$104,315 | -$106,452 | -$72,254 |
| % Margin | – | – | -1,315.2% | -530.5% |
| Other Income/Exp. Net | $5,031 | $8,300 | $20,471 | $66 |
| Pre-Tax Income | -$124,697 | -$96,015 | -$85,981 | -$72,188 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$124,697 | -$96,015 | -$85,981 | -$72,188 |
| % Margin | – | – | -1,062.3% | -530% |
| EPS | -3.06 | -4.83 | -10.1 | -10.14 |
| % Growth | 36.6% | 52.2% | 0.4% | – |
| EPS Diluted | -3.06 | -4.83 | -10.1 | -10.14 |
| Weighted Avg Shares Out | 40,817 | 19,884 | 8,512 | 7,118 |
| Weighted Avg Shares Out Dil | 40,817 | 19,884 | 8,512 | 7,118 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,469 | $7,142 | $2,616 | $64 |
| Interest Expense | $340 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,455 | $2,581 | $2,408 | $2,964 |
| EBITDA | -$121,902 | -$93,434 | -$96,866 | -$69,290 |
| % Margin | – | – | -1,196.8% | -508.7% |